Join the club for FREE to access the whole archive and other member benefits.

Johan Auwerx

Professor at the École Polytechnique Fédérale in Lausanne.

Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he directs the Laboratory for Integrated and Systems Physiology (LISP). Dr. Auwerx uses molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focuses on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors – a particular class of transcription factors – into drugs, which are now used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.

Founder of Academy for Health & Lifespan Research.

Visit website:

See also: Institute Swiss Federal Institute of Technology Lausanne (EPFL) - University that specializes in natural sciences and engineering.

Mentioned in this Resource


World's aging researchers unite to accelerate breakthroughs in longevity.

Johan Auwerx is also referenced in the following:


World's aging researchers unite to accelerate breakthroughs in longevity.


Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen

Johan Auwerx News

Restructured mitochondrial metabolism linked to survival of human eggs

STAT - 20-Jul-2022

Complex I production temporarily halted in quiescent oocytes, promoting fertility


Boosting NAD+ reverses muscle ageing and associated diseases

Medical Xpress - 19-Jan-2021

Drugs boosting NAD+ target toxic proteins by turning on the mitochondrial function